Bisphosphonate-associated osteonecrosis of the jaws

Climacteric

Volumn 10, Issue 1, 2007, Pages 5-8

  Goss, A N ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Bisphosphonates; Bone disease; Osteonecrosis of the jaws

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE GLUCONATE; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; BONE METASTASIS; BONE NECROSIS; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; EDITORIAL; HEAD AND NECK CANCER; HUMAN; HYPERCALCEMIA; JAW; JAW DISEASE; MULTIPLE MYELOMA; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; SOFT TISSUE INFECTION; TOOTH IMPLANTATION;

BONE NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; DIPHOSPHONATES; FEMALE; HUMANS; JAW; JAW DISEASES; OSTEONECROSIS; OSTEOPOROSIS;

EID: 33847113863     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130601176726     Document Type: Editorial

References (20)

1. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-17
3. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4
4. Carter GD, Goss AN. Letter to the editor. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 2003;48:268
5. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005;182:417-18
6. www.medicareaustralia.gov.au/cgi-bin/broker.exe
7. Hoff AO, Toth B, Altunag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Bone Miner Res 2005;20(Suppl 1):1218
8. Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofacial Radiol 2006;35:236-43
9. Carter GD, Doecke C, Goss AN. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005;182:413-15
10. Cheng A, Mavrokokki A, Carter G, et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 2005;50(Suppl 2)
11. Fleisch H. Bisphosphonates: mechanisms of action. Endocrine Rev 1998;19:80-100
12. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61
13. Ashcroft J. Bisphosphonates and phossy-jaw: breathing new life into an old problem. Lancet Oncol 2006;7:447-9
14. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14
15. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006;May-Jun(3):349-53
16. Mavrokokki A, Cheng A, Stein B, Goss AN. The nature and incidence of bisphosphonate associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;in press
17. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/ osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75
18. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis. J Am Dent Assoc 2005;136:1658-68
19. Expert Panel Recommendations for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws: June 2004. Professional Education Material. East Hanover, NJ: Novartis, 2004.
20. Woo SB, Hellstein JW, Kalmer JR. Systematic review. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761